EYE vs. PRCT, IRTC, NVST, TMDX, SLNO, ENOV, LIVN, NVCR, WRBY, and LMAT
Should you be buying National Vision stock or one of its competitors? The main competitors of National Vision include PROCEPT BioRobotics (PRCT), iRhythm Technologies (IRTC), Envista (NVST), TransMedics Group (TMDX), Soleno Therapeutics (SLNO), Enovis (ENOV), LivaNova (LIVN), NovoCure (NVCR), Warby Parker (WRBY), and LeMaitre Vascular (LMAT). These companies are all part of the "medical equipment" industry.
National Vision vs.
PROCEPT BioRobotics (NASDAQ:PRCT) and National Vision (NASDAQ:EYE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, community ranking, dividends and institutional ownership.
National Vision has higher revenue and earnings than PROCEPT BioRobotics. National Vision is trading at a lower price-to-earnings ratio than PROCEPT BioRobotics, indicating that it is currently the more affordable of the two stocks.
89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 17.4% of PROCEPT BioRobotics shares are owned by insiders. Comparatively, 2.3% of National Vision shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
National Vision received 214 more outperform votes than PROCEPT BioRobotics when rated by MarketBeat users. However, 68.97% of users gave PROCEPT BioRobotics an outperform vote while only 64.80% of users gave National Vision an outperform vote.
In the previous week, PROCEPT BioRobotics had 3 more articles in the media than National Vision. MarketBeat recorded 12 mentions for PROCEPT BioRobotics and 9 mentions for National Vision. PROCEPT BioRobotics' average media sentiment score of 1.14 beat National Vision's score of 0.82 indicating that PROCEPT BioRobotics is being referred to more favorably in the media.
PROCEPT BioRobotics presently has a consensus target price of $94.29, indicating a potential upside of 52.66%. National Vision has a consensus target price of $14.00, indicating a potential upside of 5.58%. Given PROCEPT BioRobotics' stronger consensus rating and higher possible upside, research analysts plainly believe PROCEPT BioRobotics is more favorable than National Vision.
PROCEPT BioRobotics has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500. Comparatively, National Vision has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500.
National Vision has a net margin of -0.81% compared to PROCEPT BioRobotics' net margin of -50.07%. National Vision's return on equity of 3.52% beat PROCEPT BioRobotics' return on equity.
Summary
PROCEPT BioRobotics beats National Vision on 10 of the 18 factors compared between the two stocks.
Get National Vision News Delivered to You Automatically
Sign up to receive the latest news and ratings for EYE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
National Vision Competitors List
Related Companies and Tools
This page (NASDAQ:EYE) was last updated on 3/27/2025 by MarketBeat.com Staff
Buy EYE Stock Free EYE Stock Alerts